The spatial‐hindrance‐based Ab lock can be completely removed from pro‐Adalimumab after protease cleavage at the RA region, thus restoring the TNFɑ‐binding ability of Adalimumab and enhancing the efficacy of RA therapy in the presence of anti‐Id Ab. The gene discussed is TNF; the disease is rheumatoid arthritis.